2025 Targeted Therapies of Lung Cancer (TTLC) - Posters-PP01.54 High-Dimensional Immunophenotyping of Patients with Localized Non-Small Cell Lung Cancer (NSCLC) Reveals Distinct Immune Cell Subsets Predictive of Disease-Free Survival (DFS) in AFT-16 and LCMC3 Datasets

PP01.54 High-Dimensional Immunophenotyping of Patients with Localized Non-Small Cell Lung Cancer (NSCLC) Reveals Distinct Immune Cell Subsets Predictive of Disease-Free Survival (DFS) in AFT-16 and LCMC3 Datasets

Back to course

Pdf Summary

The document outlines a study utilizing the "IMMUNOME" panel, a high-dimensional flow-cytometry-based immunophenotyping method, to analyze immune cell subsets. Specifically, the research aims to identify immune cell surface marker combinations (SMCs) that predict clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs) like atezolizumab.<br /><br />Two clinical trials, LCMC3 and AFT-16, are central to this research. LCMC3 is a Phase II trial evaluating neoadjuvant atezolizumab in Stage I-III NSCLC, while AFT-16 involves neoadjuvant and adjuvant atezolizumab combined with chemoradiation for Stage III NSCLC. The primary endpoint for LCMC3 includes major pathological response (MPR) rates, while AFT-16 focuses on disease control rate at 12 weeks.<br /><br />Researchers tested the predictive ability of identified SMCs, leveraging them against RECIST responses and overall survival (OS) outcomes in both trials. In LCMC3, they identified 1139 SMCs, eventually refining this to 100 SMCs linked to treatment responses and survival. In AFT-16, the top five SMCs predicted disease-free survival (DFS) and RECIST responses effectively, with significant areas under the curve (AUCs) in ROC analyses indicating model robustness.<br /><br />Key findings include that non-T/non-NK cells expressing immune regulatory receptors (such as ILT2 and NKG2D) are positively associated with MPR. Additionally, specific SMCs are identified across various immune cell types, such as cytotoxic T-cells, NK cells, and myeloid dendritic cells, for their association with clinical outcomes.<br /><br />The study, supported by several institutions including City of Hope National Medical Center and The Ohio State University, underscores the potential of SMCs as biomarkers to predict ICI efficacy in NSCLC patients, potentially guiding personalized treatment strategies.

Asset Subtitle

Nicholas Eustace

Keywords

IMMUNOME panel

flow cytometry

immune cell subsets

non-small cell lung cancer

immune checkpoint inhibitors

atezolizumab

LCMC3 trial

AFT-16 trial

surface marker combinations

biomarkers